Company Announcement / Press release Archives - Page 2 of 17

Important information to holders of warrants series TO6: subscription period begins today

Holders of Xspray's warrants series TO6 can, during the period 18 April – 2 May 2024, subscribe for new shares in Xspray Pharma (“Company”) at a price of SEK 40. The warrants were allotted as part of the subscribed units in the rights issue in June 2023. The proceeds from subscribed warrants will be used […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 21 May 2024 at 10.00 CET at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CET. The shareholders may exercise their voting rights at the annual general meeting by attending […]

Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants

Xspray Pharma has received written declarations of intent whereby owners of approximately 50 percent of shares in the company state their intent to exercise warrants TO6 to subscribe for newly issued shares during the subscription period 18 April – 2 May 2024 for the subscription price 40.00 SEK per share. “We are very pleased over […]

Xspray Pharma publishes its Annual Report 2023

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/ An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma: “Throughout 2023, we continued to make significant progress on the exciting journey toward the […]

Interim Report Fourth Quarter 2023

October-December 2023, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -54,513 thousand (-55,220) Earnings per share before dilution amounted to SEK -1.85 (-2.48) Cash flow from operating activities amounted to SEK -32,626 thousand (-35,003) Cash flow from investing activities amounted to SEK -20,729 thousand (-29,481) January-December 2023, Group […]

FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July

Stockholm, Sweden – Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY): The U.S. Food and Drug Administration (FDA) has accepted the resubmission of Xspray Pharma’s New Drug Application (NDA) for Dasynoc®, following a Complete Response Letter (CRL) where additional information was requested. The FDA has now assigned a Prescription Drug User Fee Act (PDUFA) date to […]

Xspray Pharma appoints Michael af Winklerfelt as acting CFO

Xspray Pharma has appointed Michael af Winklerfelt as acting CFO, beginning tomorrow, February 8th. The company’s current CFO Kerstin Hasselgren leaves the role at her own request and will transition to another internal role as Senior Advisor and Head of IR. Michael af Winklerfelt has extensive experience from similar roles at listed life science companies, […]

New number of shares and votes in Xspray Pharma

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the number of shares and votes in Xspray Pharma AB has changed as a result of shares being registered due to the exercise of warrants series TO5 which were issued in connection with the rights issue in June this year, and for which the subscription period […]

Xspray Pharma raises SEK 92.3 million through warrants TO5

Xspray Pharma today compiled the outcome of exercised warrants of series TO5, issued in connection with the rights issue in June this year and for which the subscription period ended on November 30, 2023. In total, 2,307,242 series TO5-warrants were exercised to subscribe for new shares. Xspray Pharma thereby receives proceeds of SEK 92.3 million […]

Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage

Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage. XS003, an amorphous non-crystalline nilotinib, designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®), is the second protein kinase inhibitor (PKI) product candidate developed with Xspray’s HyNap™ technology TASIGNA is an import treatment for chronic myeloid leukemia (CML), […]